Effect ofYang-Xue Qing-NaoGranules on Expression of GSK-3β andβ-catenin in CA1 Area of Hippocampus among Vascular Dementia Rats
10.11842/wst.2015.10.020
- VernacularTitle:养血清脑颗粒对血管性痴呆大鼠海马CA1区GSK-3β及β-catenin蛋白表达的影响＊
- Author:
Yunkun SAN
;
Yongwei LUO
;
Bin LIU
;
Yuanyuan MA
;
Wenjing MAO
;
Jinxia ZHANG
;
Shiying LI
- Publication Type:Journal Article
- Keywords:
Vascular dementia;
glycogen synthase kinase-3β;
β-catenin;
Yang-Xue Qing-Naogranules
- From:
World Science and Technology-Modernization of Traditional Chinese Medicine
2015;(10):2069-2074
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to observe the effect ofYang-Xue Qing-Nao(YXQN) granules on expressions of glycogen synthase kinase-3β (GSK-3β) andβ-catenin in CA1 area of hippocampus among vascular dementia (VD) rats. A total of 72 SD rats were randomly divided into the sham operation group, VD group (model group) and the YXQN granules treatment group (treatment group). The VD rat model was prepared by modified Pulsineli’s four-vessel occlusion. The expressions of GSK-3β andβ-catenin in CA1 area of hippocampus were detected by immunohistochemistry and western blotting at the 1st week, 2nd week, 4th weeks and 8th week after VD model operation. The results showed that expressions of GSK-3βwere increased in the model group at different time points, which were many quantities of expression at the 1st week, and a large number of expressions at the 2nd week. It reached peak at the 4th week; and began to decline but still higher at the 8th week. Compared with the sham operation group, the expression of GSK-3β was significantly increased in the model group at different time points (P < 0.01). The expression ofβ-catenin was increased in the model group at different time points. However, there was no statistical significance compared with the sham operation group (P > 0.05). Compared with the model group, expressions of GSK-3β andβ-catenin were significantly increased in the treatment group at different time points (P < 0.01). It was concluded that YXQN granules upregulated the expression of GSK-3β andβ-catenin, which may be helpful to VD treatment.
